Ireland’s biopharma sector has a generative AI problem that is not a shortage of ambition. The Generative AI for Life Sciences Playbook 2025, published on 26 September 2025 by BioPharmaChem Ireland, Connected Health Skillnet, and Brightbeam, found that many life sciences firms are stuck in proof-of-concept purgatory, running experiments that rarely scale to production value. For C-suite leaders facing the sharpest margin squeeze in years, the playbook is a timely intervention.

The diagnosis is accurate and the response proportionate. Ireland’s biopharma sector generates €116 billion in exports and employs 50,000 professionals, but its AI adoption curve lags its competitive position. The playbook merits commendation: it translates regulatory complexity into actionable frameworks, maps over 100 validated use cases across five value streams, and reframes AI as a defensive margin strategy rather than a discretionary project.

The financial pressure is concrete. The BioPharmaChem Manufacturing Report 2025 found that expected profitability growth dropped to 14%, down from 33% the prior year, squeezed by wage and energy inflation. AI is a top priority for 64% of businesses, up from 54% in 2024, and 86% are planning initiatives, up from 75%. The imperative is no longer theoretical.

The playbook identifies why adoption stalls in a GxP-regulated environment. Validation requirements, data integrity obligations, and the EU AI Act create compliance layers absent from other industries, making it harder to move from proof-of-concept to validated production deployment. Its 28 deep dives map use cases from foundational applications to high-stakes environments such as deviations management. McKinsey estimates generative AI could create between US$60 billion and US$110 billion (approximately €55 billion to €101 billion) annually for global life sciences; Ireland’s share depends on crossing the compliance gap.

The competitive context amplifies urgency. EU biopharma hubs in Flanders, Spain, and the Nordic countries have made earlier investments in digital manufacturing, putting Ireland at a disadvantage per industry commentary from January 2026. IDA Ireland data shows the sector holds a structural advantage in decades of underleveraged operational data. The EU AI Act requires transparency, traceability, and human oversight that align with GxP principles, creating a compliance pathway for well-prepared organisations.

Three priorities will determine whether Ireland escapes proof-of-concept purgatory. Pharmaceutical executives should designate AI as a board-level programme with dedicated accountability for scaling validated use cases to production. The Government should establish the AI Regulatory Sandbox with the HPRA that BioPharmaChem Ireland has requested, enabling industry to co-develop standards with regulators. Sector bodies should accelerate matched Skillnet funding to build AI fluency, as digital literacy gaps are the most cited barrier to production-scale deployment.

The Generative AI for Life Sciences Playbook 2025 provides the sector its clearest map from ambition to execution. AI is projected to add at least €250 billion to Ireland’s GDP by 2035, and the life sciences sector will be a primary contributor only if it converts pilots to scale. The countries that industrialise AI adoption fastest in regulated manufacturing will define the next competitive tier, and Ireland has the foundation to lead.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)